BiotechTube

Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate

Pre-clinicalRecruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Von Willebrand Disease, Type 3

Conditions

Von Willebrand Disease, Type 3

Trial Timeline

Apr 29, 2025 → Nov 1, 2026

NCT ID
NCT06883240

About Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate

Von Willebrand Factor Concentrates + Von Willebrand Factor Concentrates and Factor VIII Concentrates + Factor VIII Concentrates + Recombinant Activated Factor VII + Activated Prothrombin Complex Concentrate is a pre-clinical stage product being developed by Roche for Von Willebrand Disease, Type 3. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06883240. Target conditions include Von Willebrand Disease, Type 3.

What happened to similar drugs?

4 of 7 similar drugs in Von Willebrand Disease, Type 3 were approved

Approved (4) Terminated (0) Active (3)
✅Blood coagulation Factor VIII and vWF, humanCSLApproved
✅VoncentoCSLApproved
✅Alphanate SD/HTGrifolsApproved
✅plasma-derived FVIII/VWF concentrateGrifolsApproved
🔄Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing AgentsRochePhase 3
🔄BiostateCSLPhase 3
🔄BiostateCSLPhase 3

Hype Score Breakdown

Clinical
3
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06883240Pre-clinicalRecruiting

Competing Products

14 competing products in Von Willebrand Disease, Type 3

See all competitors
ProductCompanyStageHype Score
Emicizumab + von Willebrand Factor (VWF) Concentrates + Factor VIII (FVIII) Concentrates + von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates + Bypassing AgentsRochePhase 3
47
Neumega (Oprelvekin, Interleukin 11, IL-11)PfizerPhase 2
27
Oprelvekin, Interleukin 11, IL-11PfizerPhase 2
35
recombinant interleukin-11 + recombinant interleukin-11 + recombinant interleukin-11PfizerPhase 2
35
efanesoctocog alfa (BIVV001)SanofiPhase 1
29
BiostateCSLPhase 3
40
Voncento®CSLPre-clinical
26
Blood coagulation Factor VIII and vWF, humanCSLApproved
43
Biostate® + Biostate®CSLPhase 2/3
38
VWF/FVIII productsCSLPre-clinical
26
BiostateCSLPhase 3
40
VoncentoCSLApproved
43
Alphanate SD/HTGrifolsApproved
44
plasma-derived FVIII/VWF concentrateGrifolsApproved
47